Five leading scientists were ousted from the annual meeting of the American Diabetes Association (ADA) in New Orleans on Friday. Their crime: handing out copies of an editorial, published in the ...

There were extraordinary scenes at the Scientific Sessions of the American Diabetes Association (ADA) in New Orleans earlier ...

Late-breaking data for retatrutide, CagriSema, survodutide, and oral elecoglipron are poised to reshape near-term formulary strategy and utilization management for obesity and metabolic disease.

Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22. NEW ORLEANS — A senior ...

Daewon Pharmaceutical will present key preclinical data on a next-generation quadruple-action obesity drug candidate at one ...

Key obesity data from Eli Lilly, Boehringer Ingelheim and Sciwind Biosciences captivated ADA 2026 attendees.

Wider use of continuous glucose monitoring (CGM), glycemic management during cancer treatment, and individualized dosing of obesity drugs in people with diabetes are just a few of the new topics and ...

On the morning of June 5, 2026, attendees queued outside the main hall of the Ernest N. Morial Convention Center in New Orleans for the American Diabetes Association (ADA) Scientific Sessions. The ...

Experts at ADA 2026 say nutrition guidelines must be personalized, culturally responsive, and built on research that reflects the patients they're meant to serve. In a VESALIUS-CV subgroup analysis, ...

At the event, Novo Nordisk also announced that U.S. prescriptions for the pill-based version of Wegovy just hit 3 million.